Article Details
Retrieved on: 2021-04-28 16:30:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
A second issue afflicting the industry's ESG rating is affordability and pricing, with 12 firms scoring negatively on this issue. While AstraZeneca offered to ...
Article found on: www.pharmatimes.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here